Arlington, VA (PRWEB) February 21, 2013
The delivery of more cost-effective healthcare has become a worldwide challenge as the costs associated with healthcare continue to increase, driven by changing demographics, societal expectations and advances in medical technology. The introduction of alternative versions of biologic products, also known as biosimilars, into the United States market has been gaining increasing visibility as patents for many agents are nearing expiration and as the FDA moves closer to establishing a regulatory pathway for these agents. For these reasons, BioInformatics LLC is opening sponsorship opportunities for an in-depth report in this space: Manufacture of Biosimilar Drugs for the U.S. Market: Defining the Market Opportunity for Life Science Suppliers.
As scientific and analytical instrument manufactures seek to explore new markets to offset slower growth and reduced funding in academic research, attention turns to the potential for revenues generated by the pending authorization for pharmaceutical and biopharmaceutical companies to move forward with the development and commercialization of biosimilar drugs in the U.S.
The process is complicated, and the onus is on the drug manufacturers to prove that the biosimilar drugs have a similar structure and function as the original branded drugs. As with a generic small-molecule drug, biosimilars will ostensibly be less costly for the consumer and therefore enjoy a sizable demand. However, long before this nascent family of drugs can reach the market, biopharmaceutical companies will be required to ramp up their capacity to conduct the FDA-required analysis.
Or will they? Are labs going to need new instruments, or will they be able to conduct this research with their currently installed equipment? Will new features be required to achieve the biophysical characteristics and biological function of the reference standard biological drug? Which molecules will be targeted? Will new drugs be developed that go beyond the efficacy of the branded version?
These are questions that suppliers are asking and that will be addressed in the syndicated report: Manufacture of Biosimilar Drugs for the U.S. Market: Defining the Market Opportunity for Life Science Suppliers. Comprised of 25 interviews from U.S. pharmaceutical/CRO companies and 25 interviews with EU pharmaceutical/CRO companies—to include both R&D and regulatory personnel—this report will be an in-depth exploration of what the decision-makers are saying about what’s on the near horizon for biosimilar drug development.
The report is scheduled to release on May 31, 2013. The deadline to become a sponsor for this research is March 8, 2013. Click here for a more complete description of the report.
ABOUT BIOINFORMATICS LLC
BioInformatics LLC is the premier research and advisory firm serving the life science industry. By leveraging our professional social network of more than 71,000 life scientists, we have supported more than 500 companies and provided insights that lead to better business decisions. Our assignments include assessing the size and attractiveness of markets, optimizing product configurations and pricing, validating corporate acquisitions, measuring customer loyalty, and evaluating brand strength and positioning.
Read the full story at http://www.prweb.com/releases/2013/2/prweb10453683.htm.
Copyright©2012 Vocus, Inc.
All rights reserved